Triplebar

Triplebar is a biotech company specializing in low-cost animal proteins, cell lines for cultivated meats, and therapeutic drugs. The company uses a hyper-throughput screening platform integrating hardware, software, biology, and biochemistry to evolve microbes for precision fermentation and optimize cell lines for cultivated meat production. Further, this platform integrates AI/ML to accelerate solution discovery and develop libraries containing information on entire genomes. According to the company, its platform can screen permutations 10,000x faster than current best-in-class systems.

Key customers and partnerships

In January 2023, the company partnered with ingredients manufacturer FrieslandCampina to co-develop microbial cells for alternative protein applications via fermentation methodologies. In March 2023, Triplebar partnered with Umami Bioworks, a cell-cultured seafood company, to optimize cell lines for cheaper and more efficient production of cultivated foods.

Funding and financials

In October 2023, the company raised USD 20 million in funding, led by Synthesis Capital, with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and others. The funds were earmarked for scaling up production and commercializing its portfolio. Later, in January 2024, the company received additional funding of USD 1 million from Rabobank adding to the previous round.